|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
Aegera Therapeutics Announces $21 Million in Series C Funding
November 22nd, 2006 No comments
Aegera Therapeutics Inc. announced recently the first closing of their Series C financing, led by The VenGrowth Advanced Life Sciences Fund Inc. and supported by leading Canadian biotechnology funds. This $21 Million Series C Financing, including over $14 Million of equity, along with a venture debt facility of up to $7 Million, will fund the clinical advancement of Aegera’s three apoptosis programs, including two new clinical trials, in cancer and neuropathic pain, scheduled to be initiated in 2007. Commenting on this funding, Dr. Michael Berendt, Aegera’s new President and CEO declared “I am extremely excited that with this first close of our Series C funding, Aegera is poised to achieve significant clinical milestones for each of our three drug programs over the next 18 months. In addition to working very aggressively on our three internal programs, we have already begun to identify additional in-licensing and merger and acquisition opportunities that will position Aegera as one of Canada’s most exciting biotechnology companies.”
Luc Marengere, Managing General Partner at VenGrowth added, “Aegera is one of the most promising private biotechnology companies in Canada today. They have successfully made the transition from the research bench to the clinic and have the management depth, intellectual property and clinical programs to rapidly develop into a leading North American biotechnology company.”
This funding was strongly supported by other existing investors including GrowthWorks, Business Development Bank of Canada, Desjardins Venture Capital, Multiple Capital and Solidarity Fund (QFL). New investors are being solicited for a second closing of this Series C funding, early in 2007.
For more information, please visit Aegera’s website at www.aegera.com
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility